What is abemaciclib? Understanding a Targeted Therapy for Breast Cancer
•
5 min read
According to the monarchE trial, adding abemaciclib to standard hormone therapy significantly reduced the risk of invasive disease recurrence by over 25% for patients with high-risk, HR+, HER2- early breast cancer. Abemaciclib (brand name Verzenio) is a targeted cancer therapy that has revolutionized treatment for this specific patient population.
